Erlotinib Accord

( ARTG ) Non-Small cell lung cancer,ERLOTINIB ARX is indicated for the first-line treatment of patients with advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with activating EGFR mutations.,ERLOTINIB ARX is indicated for maint​​​‍​​‍​​​​‍​​‍‍enance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations who have not progressed on first-line chemotherapy.,ERLOTINIB ARX is also indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.,Pancreatic cancer,ERLOTINIB ARX in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.